[pT1G3 tumor of the bladder].
The management of the superficial bladder tumor is commonly performed by transurethral resection (TUR) and a following chemotherapy or immunotherapy with exception of Tis. A lot of doubts and questions raise in the management of pT1G3 bladder tumor (BT) for the high grade of recurrencies and progressions. Our experience from 1984 to 1994 about 109 patients (pts) with pT1G3 BT undergone to radical cystectomy (47 pts) and TUR (62 pts) allows us to state that when Tis is present a radical cystectomy is mandatory, but the TUR option must be followed to frequent and accurate random biopsies in order to discovery foci of Tis. In the case of pT1G3 monofocal there is always a therapeutic disconcerting.
Vicini
D
D
Divisione di Urologia, Ospedale Civile di Voghera.
Bettaglio
G
G
Dallera
P
P
Ruggieri
M
M
Mirando
P
P
Franceschetti
G P
GP
Sali
C
C
Picchio
G L
GL
D000283:Administration, Intravesical; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D001500:BCG Vaccine / Q000008:administration & dosage; D001706:Biopsy; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D015653:Cystectomy; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D016685:Mitomycin / Q000008:administration & dosage; D013997:Time Factors; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*
D000903:Antibiotics, Antineoplastic; D001500:BCG Vaccine; D016685:Mitomycin
Il tumore della vescica pT1 G3.